PMID- 15047657
OWN - NLM
STAT- MEDLINE
DCOM- 20041014
LR  - 20190516
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 27
IP  - 4
DP  - 2004 Apr
TI  - Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST 
      elevation myocardial infarction.
PG  - 967-71
AB  - OBJECTIVE: There are conflicting results regarding the impact of type 2 diabetes 
      on intravenous thrombolysis effectiveness during ST elevation myocardial 
      infarction (STEMI). The present study, using a continuous 12-lead 
      electrocardiogram, examined the possible association of type 2 diabetes with both 
      acute intravenous thrombolysis effectiveness and long-term prognosis in this 
      setting. RESEARCH DESIGN AND METHODS: The study included 726 consecutive subjects 
      (214 type 2 diabetic subjects) with STEMI who received intravenous thrombolysis 
      in the first 6 h from index pain and were followed up for 3.5 years. RESULTS: 
      Type 2 diabetic subjects had significantly lower incidence of sustained > or = 
      50% ST recovery than nondiabetic subjects (P = 0.03). Additionally, the former 
      required a significantly greater time interval through the achievement of this 
      criterion than the latter (P < 0.001). In both type 2 diabetic (P < 0.001) and 
      nondiabetic subjects (P < 0.001), those who had not attained > or = 50% ST 
      recovery were at significantly higher risk of cardiac death than subjects who had 
      reached this criterion. The subjects who attained the above electrocardiographic 
      criterion in > or = 60 min after thrombolysis initiation were at significantly 
      higher risk compared with those who achieved this criterion in <60 min (P = 
      0.02). However, this association was true only for type 2 diabetic subjects (P = 
      0.01) and not for nondiabetic subjects (P = 0.9). CONCLUSIONS: The present study 
      suggests that type 2 diabetes is a strong predictor of acute intravenous 
      thrombolysis failure during STEMI. This finding may significantly contribute to 
      the worse prognosis for type 2 diabetic subjects compared with nondiabetic ones 
      in this setting.
FAU - Zairis, Michael N
AU  - Zairis MN
AD  - Department of Cardiology, Tzanio Hospital, Piraeus, Greece. zairis@hellasnet.gr
FAU - Lyras, Anastassios G
AU  - Lyras AG
FAU - Makrygiannis, Stamatis S
AU  - Makrygiannis SS
FAU - Psarogianni, Paraskevi K
AU  - Psarogianni PK
FAU - Adamopoulou, Evdokia N
AU  - Adamopoulou EN
FAU - Handanis, Stelios M
AU  - Handanis SM
FAU - Papantonakos, Apostolos
AU  - Papantonakos A
FAU - Argyrakis, Spyros K
AU  - Argyrakis SK
FAU - Prekates, Athanasios A
AU  - Prekates AA
FAU - Foussas, Stefanos G
AU  - Foussas SG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Fibrinolytic Agents)
RN  - EC 3.4.- (Streptokinase)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
SB  - IM
MH  - Aged
MH  - Cohort Studies
MH  - Death
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Angiopathies/diagnosis/*drug therapy/etiology/physiopathology
MH  - *Electrocardiography
MH  - Female
MH  - Fibrinolytic Agents/administration & dosage
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnosis/*drug therapy/etiology/physiopathology
MH  - Prospective Studies
MH  - Recovery of Function
MH  - Risk
MH  - Single-Blind Method
MH  - Streptokinase/administration & dosage
MH  - *Thrombolytic Therapy
MH  - Tissue Plasminogen Activator/administration & dosage
EDAT- 2004/03/30 05:00
MHDA- 2004/10/16 09:00
CRDT- 2004/03/30 05:00
PHST- 2004/03/30 05:00 [pubmed]
PHST- 2004/10/16 09:00 [medline]
PHST- 2004/03/30 05:00 [entrez]
AID - 10.2337/diacare.27.4.967 [doi]
PST - ppublish
SO  - Diabetes Care. 2004 Apr;27(4):967-71. doi: 10.2337/diacare.27.4.967.